University of Virginia School of Medicine

Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases

Retrieved on: 
Thursday, October 19, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, University, Pharmaceutical, Health, Science, Education, Global health, Therapy, Infection, Pneumonia, Lower respiratory tract infection, UVA, Asthma, Bacteria, Area studies, CXCL10, Anthrax, Safety, Pain management, Depression, University of Virginia School of Medicine, Anxiety, Patient, Peptide, COPD, Pharmaceutical industry, Medical device, Medicine

Qnovia, Inc., a pharma company developing inhaled therapeutics across a variety of indication areas, today announced it has entered into a drug development collaboration with the University of Virginia (UVA) to advance novel inhaled-drug candidates for treating bacterial infections in the lungs.

Key Points: 
  • Qnovia, Inc., a pharma company developing inhaled therapeutics across a variety of indication areas, today announced it has entered into a drug development collaboration with the University of Virginia (UVA) to advance novel inhaled-drug candidates for treating bacterial infections in the lungs.
  • “We are delighted to be working with the team at UVA to combine their exciting work on lead-series antimicrobial peptides with our inhaled drug delivery platform.
  • We believe our technology has the potential to provide meaningful therapeutic options for patients combating life-threatening infectious diseases,” said Brian Quigley, Qnovia’s Chief Executive Officer.
  • Additional high-priority indication areas for the inhaled delivery of UVA’s bactericidal peptides using Qnovia’s drug delivery platform will continue to be explored as part of the agreement.

Merck Manuals Details Different Types of Ear Infections

Retrieved on: 
Tuesday, October 3, 2023
Infection, Elbow, University, Ear, Hearing loss, Drainage, Otitis, Parent, Cochlea, Eustachian tube, Language, University of Virginia School of Medicine, Pain, Swimming, Editorial, Patient, MD, Swelling, Child, Water, Thumb, Diagnosis, Vertigo, Virginia School for Girls, Mineral oil, Dentistry, Birth control

RAHWAY, N.J., Oct. 3, 2023 /PRNewswire/ -- Most of us can remember the intense pain and bubble gum-flavored medicine that accompanied ear infections as kids. But not all ear infections are the same, and understanding the differences can be key to effective diagnosis and treatment.

Key Points: 
  • In a new editorial from MerckManuals.com, Bradley W. Kesser, MD, University of Virginia School of Medicine, details the different parts of the ear and how infections in each area differ.
  • The ear is made up of three parts – the external ( outer ear ), middle ear , and internal ( inner ear ).
  • Infections in the canal portion of the outer ear are often referred to as swimmer's ear .
  • For outer ear infections, a thorough cleaning of the ear along with a topical antibiotic applied directly to the outer ear is typically recommended.

Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults

Retrieved on: 
Thursday, September 28, 2023
Blood pressure, DBSA, Depression, University, DSM-IV codes, Pharmacy, COVID-19, Quality of life, University of California, Gepirone, CNS, Weight gain, University of Virginia School of Medicine, Fabre-Kramer Pharmaceuticals, Dizziness, MDD, Severe cutaneous adverse reactions, MD, Patient, NCE, Effectiveness, Grammatical mood, Nausea, Heart rate, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Neurology, Virginia School for Girls, Food, Chair, Pharmaceutical industry, Dietary supplement, Psychiatry

HOUSTON, Sept. 28, 2023 /PRNewswire/ -- Fabre-Kramer Pharmaceuticals Inc. (Fabre-Kramer), a biopharmaceutical company committed to developing novel therapies to address unmet needs in psychiatry and neurology, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved Exxua™ (gepirone hydrochloride extended-release tablets) for the treatment of major depressive disorder (MDD) in adults. Exxua represents a new class of antidepressant; the first and only approved antidepressant with a novel mechanism of action that selectively targets the serotonin 1A receptor, a key regulator of mood and emotion. Exxua has been shown to effectively relieve depressive symptoms, and its approved labeling does not contain Warnings or Adverse Reactions regarding causing sexual dysfunction or weight gain vs. placebo. Exxua is expected to be available in pharmacies in early 2024.

Key Points: 
  • EXXUA is the first new chemical entity (NCE) utilizing this single mechanism approved for the treatment of major depressive disorder.
  • Exxua has been shown to effectively relieve depressive symptoms, and its approved labeling does not contain Warnings or Adverse Reactions regarding causing sexual dysfunction or weight gain vs. placebo.
  • Studied in over 5,000 patients, EXXUA's unique mechanism of targeted single serotonin (5HT) 1a receptor agonism relieves depressive symptoms with an acceptable side effect profile.
  • Over 20 million American adults experienced major depressive disorder each year prior to the COVID-19 pandemic.

Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, MD as Chief Executive Officer

Retrieved on: 
Tuesday, July 25, 2023
Business development, IPO, University, SVKM's NMIMS, Therapy, Atlas Venture, MBA, Kellogg School, History, Sale, CAR, Virginia School for Girls, MD, Patient, CBO, Brown University, Broad arrow, Wilderness medicine, Conjugation, ADC, Cyrus, University of Virginia School of Medicine, Spacecraft, Bluebird bio, Antibody-drug conjugate, Northwestern University, Pharmaceutical industry, Novartis

LONDON and CAMBRIDGE, Mass., July 25, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive Officer.

Key Points: 
  • LONDON and CAMBRIDGE, Mass., July 25, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive Officer.
  • Dr. Mozayeni joins Pheon with over 20 years of experience in the biotechnology industry and a strong history of driving strategic business growth.
  • Cyrus Mozayeni, Chief Executive Officer of Pheon Therapeutics, said: "Pheon has a uniquely differentiated and preclinically validated approach to discovering and developing ADC therapeutics.
  • Jeff Albers, Chairman of Pheon Therapeutics, commented: "Cyrus' extensive experience and a proven track record, make him the ideal person to guide Pheon through our next stage of Company growth.

Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, MD as Chief Executive Officer

Retrieved on: 
Tuesday, July 25, 2023
Business development, IPO, University, SVKM's NMIMS, Therapy, Atlas Venture, MBA, Kellogg School, History, Sale, CAR, Virginia School for Girls, MD, Patient, CBO, Brown University, Broad arrow, Wilderness medicine, Conjugation, ADC, Cyrus, University of Virginia School of Medicine, Spacecraft, Bluebird bio, Antibody-drug conjugate, Northwestern University, Pharmaceutical industry, Novartis

LONDON and CAMBRIDGE, Mass., July 25, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive Officer.

Key Points: 
  • LONDON and CAMBRIDGE, Mass., July 25, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive Officer.
  • Dr. Mozayeni joins Pheon with over 20 years of experience in the biotechnology industry and a strong history of driving strategic business growth.
  • Cyrus Mozayeni, Chief Executive Officer of Pheon Therapeutics, said: "Pheon has a uniquely differentiated and preclinically validated approach to discovering and developing ADC therapeutics.
  • Jeff Albers, Chairman of Pheon Therapeutics, commented: "Cyrus' extensive experience and a proven track record, make him the ideal person to guide Pheon through our next stage of Company growth.

Bloom Health Centers expands its reach with a new Charlottesville location, bringing top-quality mental health closer to the community

Retrieved on: 
Monday, June 26, 2023
Insurance, Medicare, Medicaid, Quality of life, University of Virginia School of Medicine, Mental health, Patient, Mental, Hospital, Nursing

With a strong commitment to providing high-quality psychiatric healthcare, Bloom Health Centers is poised to revolutionize mental health services in the region.

Key Points: 
  • With a strong commitment to providing high-quality psychiatric healthcare, Bloom Health Centers is poised to revolutionize mental health services in the region.
  • The new Bloom Health Centers facility in Charlottesville marks the organization's 12th location, expanding their reach and impact in delivering comprehensive psychiatric healthcare services.
  • The new Bloom Health Centers facility in Charlottesville will offer a wide range of psychiatric services, catering to the diverse needs of individuals seeking mental health support.
  • The Bloom Health Centers team is dedicated to creating a safe and supportive environment for patients to embark on their mental health journey.

UPLIZNA® (inebilizumab-cdon) Pivotal Trial Publication Integrating MRI and Biomarker Evaluation Shows Accuracy and Uniformity of Attack Diagnoses for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Retrieved on: 
Monday, June 12, 2023
Other Health, Research, General Health, Pharmaceutical, Optical, Genetics, Clinical Trials, Science, Biotechnology, Neurology, FDA, Health, Optic neuritis, Multiple Sclerosis Journal, Myelitis, Central nervous system, Attack, University, Glial fibrillary acidic protein, Serum, AC, Multiple sclerosis, University of Virginia School of Medicine, MRI, Virginia School for Girls, Risk, Neuromyelitis optica spectrum disorder, Neuro, Horizon, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Disease, Pharmaceutical industry, Medical device, Medical imaging, NMOSD

Properly defining NMOSD attacks is essential to inform treatment decisions, yet there are no universally accepted criteria for accurate and objective diagnosis of NMOSD attacks.

Key Points: 
  • Properly defining NMOSD attacks is essential to inform treatment decisions, yet there are no universally accepted criteria for accurate and objective diagnosis of NMOSD attacks.
  • The N-MOmentum pivotal trial, which demonstrated UPLIZNA reduced the risk of attacks associated with the disease, introduced a new approach for attack analysis.
  • Attacks were evaluated by an adjudication committee (AC, comprised of two neurologists and one neuro-ophthalmologist).
  • MRI and sGFAP biomarker findings provided additional specificity in the attack adjudication process.

The Exceptional Women Alliance (EWA) announces selection of Dr. Meghan McGovern, Owner and Plastic & Reconstructive Surgeon, RenewalMD, as a 2023 Awardee

Retrieved on: 
Wednesday, June 14, 2023
Plastic surgery, Patent, Volition (psychology), University, Life, Lehigh Valley Hospital–Cedar Crest, EWA, Generosity, American Board of Plastic Surgery, Woman, American Board of Commissioners for Foreign Missions, Virginia School for Girls, Patient, Spirit, Plastic, University of Virginia School of Medicine, LOS, Culture, American College, General surgery, Dentistry, Nursing

LOS ANGELES, June 14, 2023 /PRNewswire-PRWeb/ -- The Exceptional Women Alliance (EWA) announces the selection of Winter 2023 awardee, Dr. Meghan McGovern, Owner and Plastic & Reconstructive Surgeon at RenewalMD. She is trained and educated in the classical tradition and earned her Doctor of Medicine degree at the University of Virginia School of Medicine. She then spent the next six years engaged in surgical training at Lehigh Valley Hospital in Allentown, Pennsylvania. She completed the combined program in General Surgery and Plastic and Reconstructive Surgery.

Key Points: 
  • The Exceptional Women Alliance (EWA) announces that after an expansive search and in-depth interview process, Dr. Meghan McGovern, Owner and Plastic & Reconstructive Surgeon, RenewalMD, was selected as a Winter 2023 EWA.
  • LOS ANGELES, June 14, 2023 /PRNewswire-PRWeb/ -- The Exceptional Women Alliance (EWA) announces the selection of Winter 2023 awardee, Dr. Meghan McGovern, Owner and Plastic & Reconstructive Surgeon at RenewalMD.
  • She then spent the next six years engaged in surgical training at Lehigh Valley Hospital in Allentown, Pennsylvania.
  • She completed the combined program in General Surgery and Plastic and Reconstructive Surgery.

Dr. John C. Lantis named Editor-in-Chief of HMP Global's WOUNDS journal; Dr. Terry Treadwell transitions to Editor-in-Chief Emeritus

Retrieved on: 
Tuesday, May 30, 2023
Lantis, Biochemistry, Editorial board, MEDLINE, World Association of Medical Editors, WHS, Podiatry, Patient, Greater New York, Virginia School for Girls, Heart, Vice, University, Physician, Research, Strategic planning, University of Virginia School of Medicine, American Board of Commissioners for Foreign Missions, Regeneration, Biology, Wound healing, National Harbor, Maryland, Abstract, SAWC, Morningside Hospital (Oregon), Baptist Medical Center, Assistant, Publication, Symposium, Association for the Advancement of Wound Care, History, PM, Icahn School of Medicine at Mount Sinai, DLS, World Association for Medical Law, Medical director, Management, Medical device, Nursing, Journal, D.C, Autumn, Mount Sinai West, Wound

MALVERN, Pa., May 30, 2023 /PRNewswire-PRWeb/ -- HMP Global's industry-leading journal WOUNDS today announced that Dr. John C. Lantis II is the new Editor-in-Chief, with Dr. Terry Treadwell transitioning to the role of Editor-in-Chief Emeritus. The journal has also announced that Dr. Vickie R. Driver will be named as a Clinical Editor. The new leadership will guide the journal's management and strategic planning as the premier peer-reviewed publication features a growing body of practice-changing research in wound care.

Key Points: 
  • MALVERN, Pa., May 30, 2023 /PRNewswire-PRWeb/ -- HMP Global's industry-leading journal WOUNDS today announced that Dr. John C. Lantis II is the new Editor-in-Chief, with Dr. Terry Treadwell transitioning to the role of Editor-in-Chief Emeritus.
  • The journal has also announced that Dr. Vickie R. Driver will be named as a Clinical Editor.
  • Dr. Lantis is the Site-Chief of Surgery at the Mount Sinai West Hospital and professor of surgery at the Icahn School of Medicine at Mount Sinai.
  • Dr. Treadwell first joined the WOUNDS Editorial Advisory Board in 2002 and has been the Editor since January 2007.

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

Retrieved on: 
Thursday, April 6, 2023
University, Obstetrics, Friends, Physician, Cancer, Woman, CMO, American College of Physicians, Endometrial cancer, Patient, Gynaecology, University of Virginia School of Medicine, American College, Wyeth, Therapy, Family, News, Virginia School for Girls, Pfizer, Pharmaceutical industry, Bayer

NEWTOWN, Pa., April 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that its Chief Medical Officer (CMO) Mark Gelder, M.D., recently passed away unexpectedly.

Key Points: 
  • NEWTOWN, Pa., April 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that its Chief Medical Officer (CMO) Mark Gelder, M.D., recently passed away unexpectedly.
  • Michael Saunders, M.D., has been appointed the interim Chief Medical Officer of the Company.
  • “The entire Onconova family is deeply saddened by the loss of our beloved friend and colleague,” said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova.
  • He was an accomplished industry leader with more than 35 years of experience in clinical development, medical affairs, and medical marketing.